Albert Bourla
Born 1961 · Age 64
Greek-American veterinarian and businessman; chairman and CEO of Pfizer. Joined Pfizer in 1993, led multiple business units, became CEO Jan 1, 2019, and led Pfizer's COVID-19 vaccine effort with BioNTech.
Compare Your Trajectory
See how your career milestones stack up against Albert Bourla and other industry leaders.
Life & Career Timeline
Born in Thessaloniki, Greece
Albert Bourla was born in Thessaloniki to Sephardi Jewish parents; family Holocaust history shaped his background.
Earned veterinary doctorate (DVM) — Aristotle University
Completed veterinary degree at the Veterinary School of Aristotle University of Thessaloniki (often referenced as a doctorate/DVM earned in 1985).
Ph.D. thesis completed: melatonin implants in rams
Doctoral thesis titled 'Effect of melatonin implants on sperm characteristics and on the freezability of Karagouniki ram semen' (listed as 1991).
Joined Pfizer (animal health division in Greece)
Hired as a doctor of veterinary medicine and technical director for Pfizer's animal health division in Greece — first role at Pfizer.
Left Greece after Pfizer promotion
Left Greece with his wife after a Pfizer promotion; thereafter lived in multiple cities and countries over his career.
Immigrated to the United States
Relocated to the U.S. as part of his Pfizer career progression.
Area President, Animal Health (Europe, Africa & Middle East)
Appointed area president for Pfizer Animal Health for Europe, Africa and the Middle East (served 2005–2009).
Promoted launch of Improvac in Europe
Led and promoted the launch of Improvac (an immunocastration product for pigs to reduce boar taint) on the European market.
Oversaw Europe/Africa/Asia Pacific animal health operations
In 2009–2010 oversaw Pfizer's operations across Europe, Africa and Asia Pacific; managed integration of Wyeth's Fort Dodge Animal Health in those regions.
President & GM, Established Products Business Unit
Led Pfizer's Established Products unit (2010–2013), working on business for drugs that had recently lost patent exclusivity.
Built business for off-patent drugs (Established Products)
As head of Established Products, Bourla expanded business for drugs that had lost patent exclusivity, an important commercial role.
Managed product/region integrations following Wyeth acquisition
During his roles circa 2009–2013, managed integration of Wyeth's Fort Dodge Animal Health operations into Pfizer across various regions.
Helped launch Eliquis (anticoagulant) and Ibrance (breast cancer drug)
As part of leadership of global vaccines/oncology/consumer healthcare, contributed to commercialization and launches of Eliquis and Ibrance.
Group President: Vaccines, Oncology & Consumer Healthcare
Served as group president Jan 2014–Jan 2016; led Pfizer work on cancer and heart drugs and helped launch drugs including Eliquis and Ibrance.
Group President, Pfizer Innovative Health
Served as group president of Pfizer Innovative Health from Feb 2016 to Dec 2017; oversaw a business that increased revenue by ~11% during his tenure.
Elected to Biotechnology Innovation Organization (BIO) governing board
Listed as on BIO's Health Section Governing board; BIO announced new board officers/members June 6, 2016.
Pfizer creates COO role for Albert Bourla (announced)
Pfizer established the Chief Operating Officer role for Bourla (announcement in Nov 2017) as part of succession planning.
Became Pfizer Chief Operating Officer (COO)
Took on COO role overseeing drug development, manufacturing, sales and strategy starting Jan 1, 2018.
Elected to Pfizer Board of Directors
Joined Pfizer's board of directors (February 2018) while serving as COO.
Announced as successor to Ian Read — to become CEO
Pfizer announced in October 2018 that Bourla would succeed Ian Read as CEO effective Jan 1, 2019.
Named by Institutional Investor as America's top CEO in pharma (2020 ranking noted)
Institutional Investor ranked Bourla as America's top CEO in the pharmaceutical industry in 2020; recognition surfaced in 2019–2020 coverage of his leadership.
Became Pfizer Chief Executive Officer (CEO)
Officially assumed role of Chairman and Chief Executive Officer on Jan 1, 2019, succeeding Ian Read.
Co-Chair, Partnership for New York City (board leadership)
Listed as Co-Chair of the Partnership for New York City board (timing highlighted in multiple bios around 2019).
Chair of Pfizer Foundation & PhRMA Board leadership (as listed by Pfizer site)
Pfizer executive biography lists Bourla as Chair of the Pfizer Foundation and Chair of the Board of PhRMA (dates not precisely specified in the source).
Bourla publicly stated pricing opposition to government interference
Publicly argued against government interference in pharmaceutical pricing, saying it could hamper investment in drug development (position cited during hearings/interviews).
Testified in Senate hearing on prescription drug prices
One of seven pharma CEOs who participated in a Feb 2019 hearing with the U.S. Senate Committee on Finance about prescription drug pricing.
Prix Galien Greece: 'Preeminent Greek Leader' award
Presented with the Prix Galien Greece award for Preeminent Greek Leader at ceremony in April 2019.
Joined Catalyst board
Named to the board of Catalyst (global nonprofit focused on advancing women) — announcement on April 4, 2019.
Pfizer invested >$2 billion at-risk for COVID-19 vaccine development
Under Bourla's leadership Pfizer refused public funding and invested more than $2 billion at-risk to speed development with BioNTech.
Assumed role of Executive Chairman (additional to CEO)
Assumed the additional post of Executive Chairman in January 2020 upon the retirement of Ian Read.
Directed vaccine donations and medical aid to benefit Greece and refugees
Organized vaccine donations, medical aid for refugees, and donated more than $1M in medicine to help uninsured patients in Greece.
Directed Pfizer Artificial Intelligence Center initiative (hometown)
Reportedly helped establish Pfizer's AI Center in his hometown (Thessaloniki) and drove Pfizer participation in local initiatives and fairs to benefit Greece.
Accusations of profiteering over vaccine pricing (public controversy)
Faced criticism from public health figures (e.g., Tom Frieden) over Pfizer's pandemic pricing strategy—described by some as 'war profiteering'.
Reshaped Pfizer focus: divested non-science businesses and increased R&D
As CEO, Bourla accelerated Pfizer's transformation toward being more science-driven—divesting non-science businesses and boosting R&D/digital budgets.
Received $21 million compensation from Pfizer
Reported compensation of $21 million for 2020 (widely reported figure).
At-risk manufacturing to enable immediate shipment on approval
Bourla made the decision to manufacture vaccine doses before regulatory approval so shipments could begin immediately after authorization.
Published early Phase 3 data: Pfizer–BioNTech vaccine >90% effective
Pfizer released early efficacy data in Nov 2020 showing the vaccine was more than 90% effective — a major milestone in COVID-19 response.
BBC/UK medical ethics regulator ruling regarding statements on vaccinating children
Following a December 2021 BBC interview in which Bourla praised vaccination of children, the UK regulator found Pfizer had breached ethical code in that instance.
Named Carnegie Corporation 'Great Immigrants' honoree
Carnegie Corporation recognized Bourla as an honoree of its Great Immigrants Award in 2021.
Pfizer delivered first FDA-authorized oral antiviral for COVID-19 (program milestone)
A year after the vaccine, Pfizer delivered an FDA-authorized oral antiviral treatment for COVID-19, applying 'lightspeed' approaches used in vaccine program.
CNN Business 'CEO of the Year' and Crain's NY Business Hall of Fame induction
Named CNN Business CEO of the Year (2021) and inducted into Crain's New York Business Hall of Fame.
Awarded the $1 million Genesis Prize
Awarded the 2022 Genesis Prize ($1 million) for leadership in development of the Pfizer–BioNTech COVID-19 vaccine; later directed the prize to Holocaust education initiatives in Greece.
Donated Genesis Prize money to Holocaust education and museum efforts
Directed the $1 million Genesis Prize to fund Holocaust education and the Holocaust Museum of Greece in Thessaloniki.
Received Double Helix Medal for COVID-19 vaccine leadership
Awarded the 2022 Double Helix Medal for spearheading Pfizer's COVID-19 vaccine development.
Received Golden Cross of the Order of the Redeemer (Greece)
Reportedly conferred the Golden Cross of the Order of the Redeemer by the President of Greece (news item dated April 5, 2022).
Pfizer Purpose Blueprint established (company culture initiative)
Bourla and leadership established Pfizer's Purpose Blueprint with core values: Courage, Excellence, Equity, and Joy (initiative emphasized in leadership bios).
Book recognition: 'Moonshot' Bronze Axiom award and Jewish Book Awards finalist
His book 'Moonshot: Inside Pfizer's Nine-Month Race to Make the Impossible Possible' was a Bronze Medalist in the 2023 Axiom Awards and a Finalist for the National Jewish Book Awards; was also on the WSJ bestseller list.
Reported total compensation of $21.5 million (2023 total)
In 2023, Bourla's reported total compensation from Pfizer was $21.5 million, with media reporting a CEO-to-median-worker pay ratio of 291-to-1.
Named to Time's list: Top 100 Most Influential People in Health
Included in Time magazine's 2024 list of Top 100 most influential people in health.
Invited guest to White House state dinner (President Ruto of Kenya)
Invited as among guests to the state dinner hosted by U.S. President Joe Biden in honor of Kenyan President William Ruto (May 2024).
Received New York Academy of Sciences inaugural Visionary Award
Presented with the NYAS inaugural Visionary Award in recognition of leadership and 'anything is possible' attitude driving Pfizer's vaccine development (Soirée, May 12, 2025).
Defended Israel during meeting where allegations were raised
Reportedly defended Israel against allegations of genocide raised by an attendee during a July 15, 2025 meeting (reported incident).
Key Achievement Ages
Explore what Albert Bourla and others achieved at these notable ages:
Similar Trajectories
Gavin Andresen
Born 1966 · Age 59
Software developer best known for early and central contributions to Bitcoin; former lead developer of the Bitcoin Core reference implementation and founder/chief scientist of the Bitcoin Foundation. Previously worked on 3D graphics, VRML, VoIP and accessibility-focused games.
Niklas Zennström
Born 1966 · Age 59
Swedish entrepreneur and technology investor; co-founder of Kazaa, Skype, Joost, Atomico and Zennström Philanthropies. Known for pioneering peer-to-peer and VoIP services and for later venture investing through Atomico.
Om Malik
Born 1966 · Age 59
Indian-American web and technology writer, founder of Gigaom, author of Broadbandits, and longtime venture partner at True Ventures.
Paul Thurrott
Born 1966 · Age 59
Paul Thurrott (born October 29, 1966) is an award‑winning technology journalist, author, reviewer and podcaster, best known for Windows coverage, Thurrott.com and co‑hosting Windows Weekly.
Tory Burch
Born 1966 · Age 59
American fashion designer, businesswoman and philanthropist; founder, executive chairman and chief creative officer of Tory Burch LLC; founder of the Tory Burch Foundation.
Ben Horowitz
Born 1966 · Age 59
Ben Horowitz (born June 13, 1966) is an American technology entrepreneur, investor, author, blogger and co-founder of the venture capital firm Andreessen Horowitz. He co-founded Loudcloud/Opsware (sold to HP in 2007) and is the author of two business books.